The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

Frederick A. Sirgel; Robin M. Warren; Erik C. Böttger; Marisa Klopper; Thomas C. Victor; Paul D. van Helden

doi:10.1371/journal.pone.0059414

Loading metrics

Open Access

Peer-reviewed

Research Article

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

Frederick A. Sirgel ,

* E-mail: fas@sun.ac.za

Affiliation DST/NRF Centre of Excellence for Biomedical TB Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Health Science, Stellenbosch University, Stellenbosch, South Africa
⨯
Robin M. Warren,

Affiliation DST/NRF Centre of Excellence for Biomedical TB Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Health Science, Stellenbosch University, Stellenbosch, South Africa
⨯
Erik C. Böttger,

Affiliations Institut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland, Nationales Zentrum für Mykobakterien, Universität Zürich, Zürich, Switzerland
⨯
Marisa Klopper,

Affiliation DST/NRF Centre of Excellence for Biomedical TB Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Health Science, Stellenbosch University, Stellenbosch, South Africa
⨯
Thomas C. Victor,

Affiliation DST/NRF Centre of Excellence for Biomedical TB Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Health Science, Stellenbosch University, Stellenbosch, South Africa
⨯
Paul D. van Helden

Affiliation DST/NRF Centre of Excellence for Biomedical TB Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Health Science, Stellenbosch University, Stellenbosch, South Africa
⨯

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

Frederick A. Sirgel,
Robin M. Warren,
Erik C. Böttger,
Marisa Klopper,
Thomas C. Victor,
Paul D. van Helden

Published: March 19, 2013
https://doi.org/10.1371/journal.pone.0059414

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Mycobacterium tuberculosis
Is the Subject Area "Mycobacterium tuberculosis" applicable to this article?

Thanks for your feedback.
Tuberculosis
Is the Subject Area "Tuberculosis" applicable to this article?

Thanks for your feedback.
Substitution mutation
Is the Subject Area "Substitution mutation" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Mutation
Is the Subject Area "Mutation" applicable to this article?

Thanks for your feedback.
Extensively drug-resistant tuberculosis
Is the Subject Area "Extensively drug-resistant tuberculosis" applicable to this article?

Thanks for your feedback.
Single nucleotide polymorphisms
Is the Subject Area "Single nucleotide polymorphisms" applicable to this article?

Thanks for your feedback.
Mutant strains
Is the Subject Area "Mutant strains" applicable to this article?

Thanks for your feedback.